FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W3150403772> ?p ?o ?g. }

• W3150403772 endingPage "596" @default.
• W3150403772 startingPage "588" @default.
• W3150403772 abstract "Clinical trials are an important therapeutic option for patients with cancer. Although financial burden in cancer treatment is well documented, the financial burden associated with clinical trials is not well understood.We conducted a survey regarding economic burden and financial toxicity in patients with cancer enrolled in phase I clinical trials for >1 month. Financial toxicity score was assessed using the Comprehensive Score for Financial Toxicity survey. Patients also reported monthly out-of-pocket (OOP) costs.Two hundred and thirteen patients completed the survey (72% non-Hispanic White; 45% with annual income ≤$60,000; 50% lived >300 miles from the clinic; 37% required air travel). Forty-eight percent of patients had monthly OOP costs of at least $1,000. Fifty-five percent and 64% of patients reported unanticipated medical and nonmedical expenses, respectively. Worse financial toxicity was associated with yearly household income <$60,000 (odds ratio [OR]: 2.7; p = .008), having unanticipated medical costs (OR: 3.2; p = .024), and living >100 miles away from the clinical trial hospital (OR: 2.3; p = .043). Non-White or Hispanic patients (OR: 2.5; p = .011) and patients who were unemployed or not working outside the home (OR: 2.5; p = .016) were more likely to report high unanticipated medical costs.Among patients with cancer participating in clinical trials, economic burden is high, and most of patients' OOP costs were nonmedical costs. Financial toxicity is disproportionally higher in patients with lower income and those who travel farther, and unexpected medical costs were more common among non-White or Hispanic patients. OOP costs can be substantial and are often unexpected for patients.The financial burden of cancer treatment is well documented, but there are limited data regarding the financial burden associated with cancer clinical trials. This study surveyed 213 patients enrolled in early-phase clinical trials. Monthly out-of-pocket costs were at least $1000 for nearly half of patients. Worse financial toxicity was associated with income <$60,000 and living farther away from the hospital. Racial/ethnic minorities had higher rates of unanticipated medical costs. These data help to quantify the high financial burden for patients and may reveal a cause of disparities in clinical trial enrollment for underrepresented populations." @default.
• W3150403772 created "2021-04-13" @default.
• W3150403772 creator A5005436649 @default.
• W3150403772 creator A5008786567 @default.
• W3150403772 creator A5026095888 @default.
• W3150403772 creator A5030273391 @default.
• W3150403772 creator A5031165814 @default.
• W3150403772 creator A5034499966 @default.
• W3150403772 creator A5043675371 @default.
• W3150403772 creator A5044840107 @default.
• W3150403772 creator A5045197829 @default.
• W3150403772 creator A5061237827 @default.
• W3150403772 creator A5062483954 @default.
• W3150403772 creator A5064540759 @default.
• W3150403772 creator A5068368047 @default.
• W3150403772 creator A5071800834 @default.
• W3150403772 creator A5071831846 @default.
• W3150403772 creator A5076426660 @default.
• W3150403772 creator A5084349853 @default.
• W3150403772 date "2021-04-21" @default.
• W3150403772 modified "2023-10-18" @default.
• W3150403772 title "Patient-Reported Out-of-Pocket Costs and Financial Toxicity During Early-Phase Oncology Clinical Trials" @default.
• W3150403772 cites W1970817600 @default.
• W3150403772 cites W2071663583 @default.
• W3150403772 cites W2098919693 @default.
• W3150403772 cites W2099354636 @default.
• W3150403772 cites W2105940636 @default.
• W3150403772 cites W2109334536 @default.
• W3150403772 cites W2110461214 @default.
• W3150403772 cites W2200220500 @default.
• W3150403772 cites W2226419169 @default.
• W3150403772 cites W2266198524 @default.
• W3150403772 cites W2407107555 @default.
• W3150403772 cites W2499590469 @default.
• W3150403772 cites W2529430742 @default.
• W3150403772 cites W2541722967 @default.
• W3150403772 cites W2587913380 @default.
• W3150403772 cites W2590341405 @default.
• W3150403772 cites W2618917184 @default.
• W3150403772 cites W2743845658 @default.
• W3150403772 cites W2800784096 @default.
• W3150403772 cites W2803076325 @default.
• W3150403772 cites W2807089810 @default.
• W3150403772 cites W2890845197 @default.
• W3150403772 cites W2911751302 @default.
• W3150403772 cites W2937533880 @default.
• W3150403772 cites W2946271860 @default.
• W3150403772 cites W2946401664 @default.
• W3150403772 cites W2946614049 @default.
• W3150403772 cites W3016802478 @default.
• W3150403772 cites W3131601015 @default.
• W3150403772 cites W4240338964 @default.
• W3150403772 cites W4256143550 @default.
• W3150403772 doi "https://doi.org/10.1002/onco.13767" @default.
• W3150403772 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/8265355" @default.
• W3150403772 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/33783054" @default.
• W3150403772 hasPublicationYear "2021" @default.
• W3150403772 type Work @default.
• W3150403772 sameAs 3150403772 @default.
• W3150403772 citedByCount "27" @default.
• W3150403772 countsByYear W31504037722021 @default.
• W3150403772 countsByYear W31504037722022 @default.
• W3150403772 countsByYear W31504037722023 @default.
• W3150403772 crossrefType "journal-article" @default.
• W3150403772 hasAuthorship W3150403772A5005436649 @default.
• W3150403772 hasAuthorship W3150403772A5008786567 @default.
• W3150403772 hasAuthorship W3150403772A5026095888 @default.
• W3150403772 hasAuthorship W3150403772A5030273391 @default.
• W3150403772 hasAuthorship W3150403772A5031165814 @default.
• W3150403772 hasAuthorship W3150403772A5034499966 @default.
• W3150403772 hasAuthorship W3150403772A5043675371 @default.
• W3150403772 hasAuthorship W3150403772A5044840107 @default.
• W3150403772 hasAuthorship W3150403772A5045197829 @default.
• W3150403772 hasAuthorship W3150403772A5061237827 @default.
• W3150403772 hasAuthorship W3150403772A5062483954 @default.
• W3150403772 hasAuthorship W3150403772A5064540759 @default.
• W3150403772 hasAuthorship W3150403772A5068368047 @default.
• W3150403772 hasAuthorship W3150403772A5071800834 @default.
• W3150403772 hasAuthorship W3150403772A5071831846 @default.
• W3150403772 hasAuthorship W3150403772A5076426660 @default.
• W3150403772 hasAuthorship W3150403772A5084349853 @default.
• W3150403772 hasBestOaLocation W31504037721 @default.
• W3150403772 hasConcept C10138342 @default.
• W3150403772 hasConcept C121608353 @default.
• W3150403772 hasConcept C126322002 @default.
• W3150403772 hasConcept C156957248 @default.
• W3150403772 hasConcept C162324750 @default.
• W3150403772 hasConcept C194828623 @default.
• W3150403772 hasConcept C29730261 @default.
• W3150403772 hasConcept C535046627 @default.
• W3150403772 hasConcept C71924100 @default.
• W3150403772 hasConceptScore W3150403772C10138342 @default.
• W3150403772 hasConceptScore W3150403772C121608353 @default.
• W3150403772 hasConceptScore W3150403772C126322002 @default.
• W3150403772 hasConceptScore W3150403772C156957248 @default.
• W3150403772 hasConceptScore W3150403772C162324750 @default.
• W3150403772 hasConceptScore W3150403772C194828623 @default.
• W3150403772 hasConceptScore W3150403772C29730261 @default.

• next